Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Proctor & Gamble Pharma Extend RNAi Pact Through 2006

This article corrects an earlier version that contained inaccurate information. The original said the agreement runs through 2008.

 

NEW YORK, Nov. 2 (GenomeWeb News) - Invitrogen and Proctor & Gamble Pharmaceuticals have extended a research service agreement through 2006, the firms said today.

 

The agreement extends a collaboration between the two companies that is several years old.

 

According to Invitrogen's CEO Greg Lucier, P&GP has been using Invitrogen's RNAi tools such as Stealth, RNAi Gateway, and lentiviral vectors in its target-identification and -validation programs.

 

Financial details were not discussed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more